Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07166419 · ClinicalTrials.gov registry record · Phase 1

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

A Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Recurrent Chronic Lymphocytic Leukemia, sponsored by Ohio State University Comprehensive Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT07166419: Recruiting Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Recurrent Chronic Lymphocytic Leukemia, sponsored by Ohio State University Comprehensive Cancer Center.

NCT07166419 is a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Recurrent Chronic Lymphocytic Leukemia that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 24 participants, below the 44-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07166419, a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Recurrent Chronic Lymphocytic Leukemia, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as CD19, CD20 and CD22, on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving TriCAR19.20.22 T cells may be safe, tolerable, and/or effective in treating patients with relapsed or refractory non-Hodgkin lymphoma, ALL and CLL.

Primary Outcome

Adverse events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 with the exception of cytokine release syndrome (CRS). CRS will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading for CRS.

Conditions Studied

Refractory Acute Lymphoblastic Leukemia Recurrent Chronic Lymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Recurrent Acute Lymphoblastic Leukemia Recurrent Non-Hodgkin Lymphoma Recurrent Transformed Chronic Lymphocytic Leukemia Recurrent Indolent Non-Hodgkin Lymphoma Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive Recurrent Lymphoblastic Lymphoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • BIOLOGICAL Autologous Anti-CD19/CD20/CD22 CAR T-cells

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2026-02-01
Est. Completion 2026-12-31
Phase Phase 1
Ohio State University Comprehensive Cancer Center

341 total trials

What NCT07166419 shows while recruiting

NCT07166419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 44-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (45% lower).

The record links to 10 conditions, with Refractory Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT07166419 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT07166419 about?

NCT07166419 is a clinical study titled "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia". This phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) that ha...

What is the current status of trial NCT07166419?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-02-01. Estimated completion is 2026-12-31.

What conditions does trial NCT07166419 study?

This clinical trial studies the following conditions: Refractory Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT07166419?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Autologous Anti-CD19/CD20/CD22 CAR T-cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT07166419?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07166419 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07166419's enrollment target sits among peer trials

24 15th of 21 higher than 5 of 21 other Refractory Acute Lymphoblastic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Refractory Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03437005 · 24 participants · Phase 1

    Alternation in the Human Microbiome With Commonly Used Topical Medications

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07166419

Source: ClinicalTrials.gov NCT07166419, the US trial registry maintained by the National Library of Medicine. NCT07166419 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.